

Localized, Systemic and Safe? The Alpha DaRT - New Radiotherapeutics which Refines Treatment in Solid Tumors

Company name Alpha TAU Medical * Website www.alphatau.com

CTO name Ronen Segal

Localized, Systemic and Safe? The Alpha DaRT - New Radiotherapeutics which Refines Treatment in Solid Tumors Ronen Segal ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS Please complete the ABSTRACT TEMPLATE online, for Biomed 2026 Company Presentations All items marked with an * are mandatory to complete The maximum number of words for this abstract is 400 Please be sure to complete the following: Company name Alpha TAU Medical * Website www.alphatau.com CTO name Ronen Segal Cell phone number & Email 0544843218 ronens@alphatau.com * Select a CATEGORY: Bio Convergence (Delete categories you are not selecting) Select one SESSION per abstract from the list below * (Delete sessions you are not selecting) “Redefining the Fight Against Cancer: New Targets, New Modalities.” You may delete the section instructions, leaving only the bolded bullet title Answers below should not exceed 60 words per question: • Executive Summary: Alpha TAU Medical develops first of its kind treatment for solid tumors based on alpha emitters. The first two indications is estimated in several B\$. More than 200 patients treated in several clinical trials. First commercialization PMDA approval in Japan expecting first FDA approval in the coming year, built a factory in Israel and two in USA. We raised around 184M\$, key partners include Oramed therapeutics and Yozma group, among many other. The management includes expert scientific founders and proven commercialization leaders. • Core Technology The Alpha DaRT is radiotherapeutic treatment based on Ra224, which creates 4 alpha emissions and through diffusion creates a killing zone of 5 mm. It is embedded on small metallic tubes which are implanted into solid tumors with several delivery systems for each organ. There isn't any tumor resistance to alpha radiation with very minimal side effects. • Product Profile/Pipeline: Receiving the first PMDA and towards an FDA approval in recurrent SCC head and neck cancer, a pilot study in the USA on pancreatic cancer following tremendous results from a clinical trial on a few dozen patients in Canada and Israel. We have done first in human treatments on rGBM, prostate and many more. • Business Strategy The strategy includes three pillars / markets – the first one is unresectable tumors with unmet need, mainly in Head and neck cancer, in which we target to get a first approval in 2026 with hopes for sales during Q4/26 or Q1/27. The second pillar is unmet indications such GBM and pancreatic cancers. The 3rd pillar includes the treatment of metastasis by triggering the immune system with combination therapies with Immunotherapeutics drugs. • What's Next? A lot of effort, clinically and preclinically, is being made towards the 3rd pillar – systematic treatment, by combining the Alpha DaRT with Immunotherapeutics drugs, such as Keytruda. A new pancreatic cancer study in France will include both percutaneous and EUS access. We continue to scale up